Reports

102 Results (Page 1 of 5)

Malaysia Markets Research Reports

Pharmaceuticals

Malaysia Cardiovascular Drugs Market Analysis

Malaysia Cardiovascular Drug Market is at around $0.22 Bn in 2022 and is projected to reach $0.30 Bn in 2030, exhibiting a CAGR of 4% during the forecast period. The market is driven by factors such as the aging population, increasing incidence of cardiovascular diseases, and enhanced screening and diagnostics. The market is dominated by key players like Pharmaniaga Berhad, Duopharma Biotech Bhd, B Braun Medical Industries (M) Sdn Bhd, Eschol Pharmaceuticals Sdn Bhd, CCM Pharmaceuticals (SGP), Pfizer Inc., Astra Zeneca, Sanofi, Zydus, and Lupin.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

Malaysia Dermatological Therapeutics Market Analysis

Malaysia Dermatological Therapeutics Market is at around $0.07 Bn in 2023 and is projected to reach $0.12 Bn in 2030, exhibiting a CAGR of 8.8% during the forecast period. The market is being driven by rising healthcare awareness, an increase in dermatological conditions, and technological advancements. The market is dominated by key players like Pharmaniaga Berhad, Duopharma Biotech Berhad, Almirall SA, Pfizer Inc., GlaxoSmithKline Plc, AbbVie Inc., Amgen Inc., Novartis AG, Roche, Sanofi, Bayer, and Johnson & Johnson.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

Malaysia Alopecia (Hair Loss) Therapeutics Market Analysis

The Malaysia Alopecia (Hair Loss) Therapeutics Market was valued at US $13 Mn in 2022, and is predicted to grow at (CAGR) of 7.7% from 2023 to 2030, to US $24 Mn by 2030. The primary factors propelling this industry forward include the notable increase in the prevalence of Alopecia (hair loss), technological advancements, and others. The industry is primarily dominated by players such as Johnson & Johnson, Lexington, Sun Pharmaceuticals, Merck, Capillus, Follica Inc., among others

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Digital Health

Malaysia Digital Therapeutics Market Analysis

Malaysia Digital Therapeutics Market is at around $10 Mn in 2023 and is projected to reach $57.47 Mn in 2030, exhibiting a CAGR of 27.4 % during the forecast period. Growing chronic illnesses, government programs, and technological developments are driving market growth. The market is dominated by key players like Naluri Hidup, DoctorOnCall, Omada Health Inc., 2Morrow Inc., Livongo Health Inc., WellDoc, Propeller Health, Canary Health, Noom Inc., and Akili Interactive Labs.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

Malaysia Allergy Therapeutics Market Analysis

Malaysia Allergy Therapeutics Market was valued at $37 Mn in 2022 and is estimated to reach $62 Mn in 2030, exhibiting a CAGR of 6.6% during the forecast period. The increased incidence of allergic illnesses and associated health issues is driving the need for allergy therapy medications. The major pharmaceutical players that are presently functioning in the market are GlaxoSmithKline, Sanofi, Novartis, Bayer, AstraZeneca, Eisai Co., Takeda Pharmaceutical Company, Pharmaniaga Berhad, Duopharma Biotech Bhd and Reckitt Benckiser.

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

Malaysia Alcohol Addiction Therapeutics Market Analysis

The Malaysia Alcohol Addiction Therapeutics Market is valued at around $1 Mn in 2022 and is projected to reach $2 Mn by 2030, exhibiting a CAGR of 6.5% during the forecast period. In Malaysia, market growth for alcohol addiction treatment is driven by heightened government involvement, a holistic approach to therapy, and improved accessibility due to economic growth, increased disposable incomes, and expanded insurance coverage and government-funded programs. The key players involved in the research, development, and distribution of Alcohol Addiction Therapeutics in Malaysia are Lundbeck, Roche, AstraZeneca, Alkermes, TEVA Pharmaceuticals, Pfizer, BioCorRx, Otsuka, Pharmaniaga, DuoPharma Biotech etc among others

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

Malaysia Actinic Keratosis Therapeutic Market Analysis

Malaysia Actinic Keratosis Therapeutic Market is expected to grow at a CAGR of 5.1% over the projected period, from $11 Mn in 2022 to about $16 Mn by 2030. The Actinic Keratosis Therapeutic Market in Malaysia is expanding steadily, propelled by many reasons such as the growing incidence of Actinic Keratosis, heightened consciousness, and enhanced accessibility owing to better healthcare facilities. Actinic Keratosis Therapeutics is being developed and marketed by a number of pharmaceutical firms, including Novartis, Amgen, Johnson & Johnson, Merck, Lumenis, and Pharmaniaga. Etc.

PUBLISHED: Jan, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

Malaysia Acute Lymphocytic Leukemia (ALL) Therapeutics Market Analysis

The Malaysia Acute Lymphocytic Leukemia (ALL) Therapeutics Market was valued at US $5 Mn in 2022, and is predicted to grow at (CAGR) of 8% from 2023 to 2030, to US $10 Mn by 2030. The key drivers of this industry include a surge in the incidence of acute lymphocytic leukemia cases, technological advancements, increased government funding initiatives, and other factors. The industry is primarily dominated by players such as Pfizer, Novartis, Kotra Pharma, Duopharma among other players

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

Malaysia Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis

The Malaysia Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US $ 1.8 Mn in 2022, and is predicted to grow at (CAGR) of 6% from 2023 to 2030, to US $ 2.9 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of autosomal dominant polycystic kidney disease, government initiatives, advanced treatment options and other factors. The industry is primarily dominated by players such as Otsuka, AceLink, Palladio, Reata, Xortx, Regulus among others

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

Malaysia Age-Related Macular Degeneration Therapeutics Market Analysis

The Malaysia Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at US $17 Mn in 2022, and is predicted to grow at (CAGR) of 9.10% from 2023 to 2030, to US $35 Mn by 2030. The key drivers of this industry include the rising trend in the prevalence of age-related macular degeneration, evolving healthcare infrastructure, and other factors. The industry is primarily dominated by players such as Regeneron Pharmaceuticals, Novartis, Bayer, Roche, and Genetech, among others

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

Malaysia Addiction Therapeutics Market Analysis

Malaysia addiction therapeutics market was valued at $16 Mn in 2022 and is estimated to reach $28 Mn in 2030, exhibiting a CAGR of 7.1% during the forecast period. The growing knowledge and understanding of mental health disorders, including substance abuse and addiction, has led to a major growth in the market for addiction therapeutics. The leading pharmaceutical companies in the addiction therapeutics market include Pfizer, GlaxoSmithKline, Novartis, Sanofi, AstraZeneca, Merck, Bayer, Abbott, Johnson & Johnson, and Boehringer Ingelheim.

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

Malaysia Adult Malignant Glioma Therapeutics Market Analysis

The Malaysia Adult Glioma Therapeutics Market is valued at around $4 Mn in 2022 and is projected to reach $7 Mn by 2030, exhibiting a CAGR of 9.1% during the forecast period. The factors attributed to market growth such as an aging population, improved diagnosis, and heightened awareness, are subsequently driving the demand for therapeutic interventions and are providing new opportunities for the expansion of the glioma therapeutics market. Key players in the Malaysia Adult Malignant Glioma Therapeutics Market include companies like Roche, Novartis, Merck & Co., Pfizer, Bristol-Myers Squibb, Emcure, Sun Pharmaceuticals, AbbVie, Pharmaniaga etc. among others.

PUBLISHED: Feb, 2024 | FORMAT: PPT | LAST UPDATED: Feb, 2024 | PRICE: $3999

Pharmaceuticals

Malaysia Vitamin and Minerals Market Analysis

This report presents a strategic analysis of the Malaysia Vitamin and Minerals Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the Malaysia Vitamin and Minerals Market, offering unmatched value, accuracy, and expert insights.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Dec, 2023 | PRICE: $3999

Pharmaceuticals

Malaysia Radiotherapy Market Analysis

By 2030, it is anticipated that the Malaysia Radiotherapy Market will reach a value of $xx Mn from $11 Mn in 2022, growing at a CAGR of xx% during 2022-2030. The Radiotherapy Therapeutics Market in Malaysia is dominated by a few domestic players such as Innopharmax Technologies, Hicom-Teck, and VHMED. The radiotherapy market in Malaysia is segmented into different types, technologies, procedures, applications, and end-users. The major risk factors associated with awareness of radiotherapy shortage of skilled staff, government initiatives, and reimbursement policy. The demand for Malaysia Radiotherapy is increasing on account of the rise in cancer cases in the country.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Dec, 2023 | PRICE: $3999

Pharmaceuticals

Malaysia Oncology Therapeutics Market Analysis

By 2030, it is anticipated that the Malaysia Oncology Therapeutics Market will reach a value of $565 Mn from $292 Mn in 2022, growing at a CAGR of 8.6% during 2022-30. The Oncology Therapeutics Market in Malaysia is dominated by a few domestic pharmaceutical companies such as Biocon Sdn Bhd, Hovid Berhad, and Pharmaniaga Berhad. The Oncology Therapeutics Market in Malaysia is segmented into different types of cancer and different therapy types. The major risk factors associated with cancer are diet, alcohol, tobacco, air pollution, and physical inactivity. The demand for Malaysia Oncology Therapeutics is increasing on account of the rise in initiatives taken by the Government of the country.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Dec, 2023 | PRICE: $3999

Clinical Trials

Malaysia Oncology Clinical Trials Market Analysis

Malaysia's oncology clinical trials market is projected to grow from $20.3 Mn in 2022 to $31.7 Mn by 2030, registering a CAGR of 5.7% during the forecast period of 2022-30. The market will be driven by the rise of oncology clinical trials in Malaysia, a well-established clinical research infrastructure, and government funding. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Novartis International AG & Biocon Malaysia.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Dec, 2023 | PRICE: $3999

Medical Devices

Malaysia Neurology Devices Market Analysis

Malaysia's Neurology Devices Market is expected to witness growth from $20 Mn in 2022 to $xx Mn in 2030 with a CAGR of xx% for the forecasted year 2022-30. The expansion of the neurology devices market in Malaysia is being fueled by the development of cutting-edge neurology devices such as brain-computer interfaces and cutting-edge neuroimaging technologies. The market is segmented by treatment, route of administration, age group, and by distribution channel. Major Key players in Malaysia's neurology devices market include Medtronic, Abbott Laboratories, Nihon Kohden, Natus Medical, and B. Braun Melsungen.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Dec, 2023 | PRICE: $3999

Healthcare Services

Malaysia Medical and Diagnostic Laboratory Service Market Analysis

This report presents a strategic analysis of the Malaysia Medical and Diagnostic Laboratory Service Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the Malaysia Medical and Diagnostic Laboratory Service Market, offering unmatched value, accuracy, and expert insights.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Dec, 2023 | PRICE: $3999

Pharmaceuticals

Malaysia Lung Cancer Therapeutics Market Analysis

By 2030, it is anticipated that the Malaysia Lung Cancer Therapeutics Market will reach a value of $91 Mn from $48 Mn in 2022, growing at a CAGR of 8.3% during 2022-30. The Lung Cancer Therapeutics Market in Malaysia is dominated by a few domestic pharmaceutical companies such as Kotra Pharma, Duopharma, and Pharmaniaga Berhad. The Lung Cancer Therapeutics Market in Malaysia is segmented into different types of cancer and different therapy types. Some of the major factors affecting the Malaysia lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies, and the presence of highly efficient drugs.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Dec, 2023 | PRICE: $3999

Pharmaceuticals

Malaysia Insulin Market Analysis

This report presents a strategic analysis of the Malaysia Insulin Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the Malaysia Insulin Market, offering unmatched value, accuracy, and expert insights.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Dec, 2023 | PRICE: $3999

Healthcare Services

Malaysia In Vitro Fertilisation (IVF) Service Market Analysis

This report presents a strategic analysis of the Malaysia In Vitro Fertilisation (IVF) Service Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the Malaysia In Vitro Fertilisation (IVF) Service Market, offering unmatched value, accuracy, and expert insights.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Dec, 2023 | PRICE: $3999

Medical Devices

Malaysia ENT Devices Market Analysis

Malaysia's ENT Devices Market is projected to grow from $40 Mn in 2022 to $60 Mn by 2030, registering a CAGR of 6% during the forecast period of 2022-30. The rising prevalence of ENT disorders, such as hearing loss, sinusitis, and tonsillitis, is a major driver of the ENT device market. The market is highly competitive, with a large number of players operating in the space, ranging from small, specialized companies to large multinational corporations. The domestic key players in the Malaysia ENT devices market include Meditop, Meditrade, and ENTtech Medical Solutions.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Dec, 2023 | PRICE: $3999

Pharmaceuticals

Malaysia Diabetes Therapeutics Market Analysis

Malaysia's diabetes therapeutics market is expected to witness growth from $231 Mn in 2022 to $492 Mn in 2030 with a CAGR of 9.9% for the forecasted year 2022-30. The increasing prevalence of diabetes and the rising urbanization in Malaysia are driving the expansion of the market. The Malaysia diabetes therapeutics market is segmented by type, application, drug, route of administration, and distribution channel. Duopharma Biotech, Iniqra Pharma, and AstraZeneca are the major players in the Malaysia diabetes therapeutics market.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Dec, 2023 | PRICE: $3999

Medical Devices

Malaysia Diabetes Devices Market Analysis

Malaysia's Diabetes Devices Market is expected to witness growth from $37 Mn in 2022 to $65 Mn in 2030 with a CAGR of 7.40% for the forecasted year 2022-30. Patients travel from all over the world to Malaysia for medical tourism, which is well-recognized for doing so. A key factor in the expansion of the diabetes device market is the availability of high-quality diabetes devices and services for patients seeking medical treatment in the country. The market is segmented by type and by the end user. Some key players in this market include GA2 Medical, Transmedia Healthcare, Johnson & Johnson, Medtronic, Roche, Ascensia Diabetes Care, and Dexcom.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Dec, 2023 | PRICE: $3999

Medical Devices

Malaysia Coronary Stents Market Analysis

Malaysia's Coronary Stents Market is expected to witness growth from $18 Mn in 2022 to $27 Mn in 2030 with a CAGR of 4.95% for the forecasted year 2022-30. The introduction of coronary stents as a treatment option for CAD is being driven by a rising desire for minimally invasive procedures in Malaysia because these procedures are less invasive and have quicker recovery times than conventional surgical procedures. The market is segmented by type, mode of delivery, materials, and end user. Some key players in this market include Qualitas Medical Group, GA2 Medical, B. Braun, Abbott Laboratories, Biotronik, Medtronic, GE Healthcare, Boston Scientific, Transmedia Healthcare, and Philips Healthcare.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: Dec, 2023 | PRICE: $3999

subscribe to our newsletter
up